Treatment with stem cells engineered to produce a signaling protein called VEGF — which drives the growth of blood vessels — was found to lead to pain relief in a mouse model of Parkinson’s disease. Researchers say engineering stem cells for use in transplant “may potentiate the therapeutic efficacy”…
Taking part in a community-based exercise program appears to help relieve the motor symptoms of Parkinson’s disease, a review study suggests. Researchers also observed that older people and those engaging in these programs for longer periods may get the most benefit. The review study, “Effects and parameters of community-based…
People with REM sleep behavior disorder (RBD) — an early nonmotor symptom of Parkinson’s disease — were significantly more likely than others to wrongly think their sense of smell was normal when olfactory deficits were evident, a small study found. Parkinson’s patients with RBD also had a diminished sense…
The C-reactive protein-to-albumin ratio (CAR), a measure of inflammation in the body that can be read from a routine blood test, may be linked to all-cause mortality in people with Parkinson’s disease, according to study of people in Japan. Data showed patients with the highest CAR were up to…
Treatment with evening primrose oil or EPO — made from the seeds of the flowering plant — was found to reduce brain inflammation and improve motor function in a rat model of Parkinson’s disease-like features, referred to as parkinsonism. A new study in Egypt found that the oil, which…
VectorY Therapeutics and Annogen have announced a new agreement to work toward developing vectorized antibody therapies for Parkinson’s disease and other neurological conditions. “We are delighted to work together with Annogen on novel tailored cell-specific promoters to enhance VectorY’s transformative AAV-vectorized antibody platform and its potential to…
Medicines for Parkinson’s disease in patients with persistent intolerable abdominal pain showed short and limited usefulness in treating this debilitating non-motor symptom, a study in Japan reported. Nonetheless, researchers found that Duodopa/Duopa,…
A Phase 2b clinical trial testing the investigational oral therapy mesdopetam, which aims to reduce levodopa-induced dyskinesia (involuntary movements) in people with Parkinson’s disease, did not reach its main goal. However, some promising reductions in dyskinesia measures were seen with the treatment. Top-line results from the trial were…
A 12-week electroacupuncture (EA) regimen in Parkinson’s disease patients along with standard medications was well tolerated and led to improved motor function and some relief from constipation, a recent study showed. Patients also reported gains in quality of life compared with those only receiving standard of care medications. “Our…
A new metric called the Parkinson’s Disease Social Functioning Scale (PDSFS) can measure social functioning in people with Parkinson’s disease, a new study reports. PDSFS scores show associations with the severity of psychiatric symptoms, suggesting better treatment of symptoms could improve patients’ ability to function in social settings, researchers…
Get regular updates to your inbox.
